Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 176,365,248
  • Shares Outstanding, K 1,241,222
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,022 M
  • EBITDA $ 12,782 M
  • 60-Month Beta 0.39
  • Price/Sales 5.97
  • Price/Cash Flow 13.26
  • Price/Book 7.61

Options Overview Details

View History
  • Implied Volatility 31.99% (+0.68%)
  • Historical Volatility 23.30%
  • IV Percentile 66%
  • IV Rank 43.86%
  • IV High 45.49% on 04/10/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 7) 3.87 (2.72%)
  • Put/Call Vol Ratio 0.66
  • Today's Volume 3,293
  • Volume Avg (30-Day) 12,332
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 155,849
  • Open Int (30-Day) 151,142
  • Expected Range 138.22 to 145.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.86
  • Number of Estimates 9
  • High Estimate $1.99
  • Low Estimate $1.73
  • Prior Year $1.81
  • Growth Rate Est. (year over year) +2.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.89 +6.12%
on 03/30/26
149.38 -4.88%
on 03/10/26
-4.54 (-3.10%)
since 03/09/26
3-Month
119.63 +18.77%
on 01/12/26
157.29 -9.66%
on 02/11/26
+20.99 (+17.33%)
since 01/09/26
52-Week
93.37 +52.18%
on 04/25/25
157.29 -9.66%
on 02/11/26
+36.84 (+35.00%)
since 04/09/25

Most Recent Stories

More News
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD)...

GILD : 142.09 (+0.39%)
TEM : 44.16 (-7.03%)
Gilead to Acquire Tubulis for Up to $5 Billion to Expand Cancer Drug Pipeline

Gilead Sciences ($GILD) said Tuesday it will acquire Germany-based Tubulis GmbH for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, as the company expands...

GILD : 142.09 (+0.39%)
BMY : 59.47 (+0.46%)
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

– Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline – – Industry Leading ADC Platform...

GILD : 142.09 (+0.39%)
Gilead Extends Tender Offer to Acquire Arcellx

Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00...

GILD : 142.09 (+0.39%)
Gilead Sciences's Q1 2026 Earnings: What to Expect

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

XLV : 149.33 (-0.23%)
$SPX : 6,824.66 (+0.62%)
GILD : 142.09 (+0.39%)
Options Action: Naked Put Trade Ideas for March 31

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

INTC : 61.72 (+4.70%)
MU : 421.51 (+3.63%)
FCX : 66.45 (+2.07%)
GILD : 142.09 (+0.39%)
DAL : 67.83 (-0.37%)
S&P Futures Waver as Concerns Over Middle East Conflict Persist, U.S. PMI Data in Focus

June S&P 500 E-Mini futures (ESM26) are trending up +0.02% this morning, swinging between gains and losses as optimism over a de-escalation in the Middle East conflict wanes.

APO : 106.98 (-0.07%)
AVGO : 354.91 (+1.22%)
JEF : 45.11 (+3.16%)
CCL : 27.85 (-0.64%)
ASML : 1,448.64 (+1.94%)
FICO : 1,072.35 (-1.80%)
ESM26 : 6,866.00 (+0.04%)
CRWV : 92.00 (+3.49%)
TSLA : 345.62 (+0.69%)
NCLH : 19.96 (-0.99%)
PUIG.E.DX : 17.300 (-1.03%)
RL : 385.14 (+2.59%)
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead Intends...

GILD : 142.09 (+0.39%)
3 Reasons to Avoid GILD and 1 Stock to Buy Instead

3 Reasons to Avoid GILD and 1 Stock to Buy Instead

GILD : 142.09 (+0.39%)
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

META : 628.39 (+2.61%)
TSLA : 345.62 (+0.69%)
GILD : 142.09 (+0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 146.40
2nd Resistance Point 144.68
1st Resistance Point 143.39
Last Price 142.09
1st Support Level 140.38
2nd Support Level 138.66
3rd Support Level 137.37

See More

52-Week High 157.29
Last Price 142.09
Fibonacci 61.8% 132.87
Fibonacci 50% 125.33
Fibonacci 38.2% 117.79
52-Week Low 93.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.